October 31, 2019 — Civil society and community-based organizations issued this letter welcoming the availability of lower-priced rifapentine, which is an essential medicine for preventing TB. However, while all the organizations agree that this discount is a step forward, they're…
Our current letter follows an earlier letter dated June 23, 2020 and calls on the Special Rapporteur for cultural rights to explicitly acknowledge the human rights dimensions of science and reaffirm the right of everyone to participate in and enjoy the benefits of scientific progress and its applications in her forthcoming communication with the United Nations General Assembly on COVID-19.
TAG's comments and recommendations to the FDA Vaccines and Related Biological Products Advisory Committee, encompassing a broad range of community concerns regarding COVID-19 vaccine development and regulatory review.
TAG and our French partners OTMeds (Observatoire de la transparence dans les politiques du médicaments) sent a letter to Sanofi CEO Paul Hudson calling on the company to reverse its efforts to patent two obvious combinations of two critical drugs to prevent tuberculosis: rifapentine and isoniazid.
On June 25, 2020, the National Black Leadership Commission on Health, the Latino Commission on AIDS, Housing Works, and TAG petitioned the New York City Board of Health to institute concrete rules to end racism as a public health crisis in New York City. TAG and partners called on the Board of Health to convene an emergency session to adopt new rules, amendments, and policies to address the disparate impact of COVID-19 on Black and Latinx New Yorkers, address racism as a public health crisis, address over-policing, and improve public health and safety.
On May 18th, TAG and 46 other organizations and individuals – including the Stop TB Partnership, Global Coalition of TB Activists, and regional networks of people living with HIV, people affected by TB, and people who use drugs – are sending this letter to authorities in the United Arab Emirates (UAE) with an urgent appeal concerning the health of people with HIV in UAE prisons who are vulnerable to COVID-19.
To encourage more equitable access to new and repurposed TB drugs, TAG signed on to letters of support for the inclusion of rifapentine, bedaquiline, delamanid, and linezolid on the WHO's Model List of Essential Medicines. The 20th Expert Committee on the Selection and Use of Essential Medicines will review drug applications and public comments in April 2015.
TAG and the TB CAB signed on to open letters to several manufacturers of U.S. Food and Drug Administration (FDA)-approved generic linezolid, including Pfizer, Teva, Glenmark, Alkem, Amneal, Macleods, Apotex, Hetero, and Sanofi urging the companies to register their respective linezolid products with the Medicines Control Council (MCC) in South Africa. Registration of additional linezolid products will address the existing effective market monopoly and extremely high prices that prevent linezolid from being offered to all patients who could benefit from its use in South Africa and countries like Swaziland that rely on the South African regulatory approval system. The co-signatories asked that following registration, companies provide linezolid at the price currently offered to country programs through the Global Drug Facility (GDF).
TAG and other U.S.-based NGOs and civil society groups sent several appeals to legislators to prioritize tuberculosis (TB) in plans for fiscal year 2017 in line with the White House’s recently released National Action Plan for Combating Multidrug-Resistant Tuberculosis. Letters to three key House and Senate subcommittees—the Labor, Health and Human Services, Education, and Related Agencies Subcommittee, the Defense Subcommittee, and the Subcommittee on State, Foreign Operations, and Related Programs.
As an organization dedicated to ensuring equitable access to critical health services to individuals and communities affected by HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV), Treatment Action Group (TAG) strongly opposes the proposed changes regarding “public charge,” published in the Federal Register on October 11, 2019 (the proposed rule).